生物材料转移协议(中英文双语版)
生物材料转移协议(中英文双语版)
XXXXX生物材料转移协议本协议确定了关于提供方向接收方所供应的由研究人员研制的特定生物材料的规定，希望在本协议的条款和细则的约束下该材料使用于非商业性研究目的。
此材料转移协议（MTA）由__________________，即一家__________________类型的组织机构(接收方)，与XXXXX（提供方）签订。
此协议于各方最后签立之日起生效，并按以下条款与细则管辖生物材料的转移和使用。
一、定义1.提供方： XXXXX2.提供方科学家：______________3.接收方：______________4.接收方科学家：______________5.原始材料：______________6.材料：原始材料、后代和未改性衍生物，其中不包括（1）改性物质（2）由接收方使用材料创制的除了改性物质、后代和未改性衍生物之外的物质。
7.后代：指源自材料的未改性后代，如源自病毒的病毒、源自细胞的细胞、源自微生物的微生物。
8.未改性衍生物：指由接收方创造的各种物质，构成一种未改性的功能亚基或原始材料的表达产物，例如未改性细胞系的亚克隆、原始材料的纯化或分馏子集，由提供方所供DNA/RNA 表达的蛋白质，或由杂交瘤细胞系分泌的单克隆抗体。
9.改性物质：指接收方创制的、包含和（或）容纳材料的物质。
10.商业用途：指向营利性机构销售、出租、授权、转移材料或其改性物质，也包括接收方在内的任何机构使用材料进行合同研究、筛选化合物库、或制造供一般销售的产品，或进行研究行为，目的是向营利性机构销售、出租、授权、转移材料或改性物质。
但是，由企业赞助的学术性研究不应被认为是材料或改性物质的商业性用途，除非满足上述对商业用途所定义的情况。
二、协议条款1.提供方保留对材料的所有权，包括任何包含或混有改性物质的材料。
2.接收方对以下材料拥有所有权：（1）改性物质（提供方对其中所含生物材料的权利保留拥有全的情况除外）；（2）使用材料或改性物质创造的非后代、未改性衍生物及改性物质（即不包含原始材料、后代或未改性衍生物）。
技术转让协议（英文）
技术转让协议（英⽂）TECHNOLOGY TRANSFER AGREEMENTTHIS TECHNOLOGY TRANSFER AGREEMENT (THIS “Agreement”) IS ENTERED INTO AS OF THIS 29TH DAY OF FEBRUARY, 2012, BY AND BETWEEN:(1) International Green Chip Co., Ltd. (英特格灵芯⽚（天津）有限公司), a limited liability company organized under the laws of the People’s Republic of China (the “PRC”) with its legal address at Room 210, South Tower, Tianda Software Zone, 80 Fourth Avenue, Tianjin Development Area, Tianjin, PRC (the “Proprietor”); and(2) iWatt Inc., a company incorporated in the State of California whose registered office is at 675 Campbell Technology Parkway, Suite 150, Campbell, CA 95008, USA. (the “Recipient”),The Proprietor and the Recipient are referred to herein each as a “Party”, and collectively, the “Parties”.RECITALSWHEREAS, the Proprietor has developed LCDTV 8CH + Boost LED BLU Driver and LCDTV TCON Bias PMIC products, the details of which are set forth on Schedule 1 attached hereto (the “Target Products”) and is the proprietor of certain know-how and confidential information relating to their designs, applications and/or manufacture;WHEREAS, the Proprietor has agreed to assign to the Recipient, and the Recipient desires to purchase from the Proprietor, full right and title to this know-how and confidential information relating the Targeted Products, for the consideration and upon the terms and conditions hereinafter set forth;WHEREAS, the Proprietor and iWatt HK Limited, a limited liability company duly established under the laws of the Hong Kong Special Administrative Region, PRC with its legal address at Unit 223B, 2/F., Core Building 2, No. 1 Science Park West Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong, have entered into an exclusive equipment lease agreement dated January 11, 2012 (as amended, the “Lease Agreement”); andWHEREAS, the Lease Agreement provides that the execution and delivery of this Agreement by the Parties shall be a condition precedent to the consummation of the transactions contemplated under the Lease Agreement.AGREEMENTNOW, THEREFORE, in consideration of the premises set forth above, the mutual covenants and agreements set forth herein and for other good and valuable consideration, the adequacy of which is hereby acknowledged, the Parties hereby agree as follows:Section 1. DEFINITION1.1 Affiliate shall mean with respect to any Party, any company that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such Party. For the purposes of this Agreement, the term “control” (and“controlling”) shall mean (i) to have at least the majority (more than fifty percent (50%)) of the voting stock of such company or (ii) the right (a) to elect the majority of the directors of such company, or (b) to direct or cause the direction of the management and policies of such company, as the case may be, where such right may be exercised without the consent of any third party.1.2 Closing shall have the meaning ascribed to such term as in the Lease Agreement.1.3 Earn Out Revenue shall mean the sales revenue of the Target Products during the 18 months immediately following the Closing, which sales revenue shall be determined by the Recipient in accordance with GAAP pursuant to Section 3.2 hereof.1.4 Effective Date shall mean the date of signing this Agreement.1.5 GAAP shall mean the generally accepted accounting principles in the United States of America in effect from time to time.1.6 Independent Advisor shall mean a suitably qualified partner in any accounting firm designated by the Recipient in writing, whose services any of the Parties is not engaging.1.7 Information shall mean collectively, all information, designs, formulae, algorithms, procedures, methods, techniques, ideas, knowledge, experiences, research and development, data, programs, subroutines, tools, materials, specifications, processes, inventions (whether patentable or unpatentable and whether or not reduced to practice), apparatus, creations, improvements, works of authorship and other similar materials, and all recordings, graphs, drawings, reports, analyses, and other writings, and other tangible embodiments of the foregoing, in any form whether or not specifically listed herein, and all related technology, regarding and relating to the materials, structures, applications and/or manufacturing of the Targeted Products, and all other information relating to the materials, manufacturing techniques and other information necessary to design, utilizeand/or manufacture the Targeted Products properly, efficiently and in reasonable quantities.1.8 Technical Documentation shall mean all manuals, recordings, graphs, drawings, reports, computer programs, calculations, special studies produced for the Target Products design and engineering activities, analyses, including but not limited to design drawings, interface drawings, manuals and stress analysis reports, relating to the design, engineering of the Target Products.Section 2. ASSIGNMENT2.1 The Proprietor hereby assigns and transfers to Recipient all rights and title (free and clear of any lien, claim, restriction, charge, security interest or other encumbrance) possessed by Proprietor in respect of the Information and the full unfettered and exclusive worldwide right to use the Information for any purpose whatsoever (including the filing of patent applications in respect of all or any aspect of it).2.2 The Recipient reserves the right to assign all of its rights, benefits and obligations under this Agreement to any of its Affiliates.Section 3. CONSIDERATION3.1 Assignment FeeThe Recipient shall pay an assignment fee of up to US$2,000,000 or RMB equivalent based on the Earn Out Revenue:(a) The Recipient shall pay US$1,000,000 or RMB equivalent if the Earn Out Revenue of the existing Target Products reachesUS$2,100,000 during the 18 months immediately following the Closing. If the Earn Out Revenue is less than US$2,100,000, such payment shall be reduced proportionally for any shortfall of the Earn Out Revenue.(b) The Recipient shall pay the remaining US$1,000,000 or RMB equivalent if the Earn Out Revenue of the existing Target Products, and any other products considered applicable by the Recipient, reaches an additional US$2,100,000 during the 18 months immediately following the Closing. If the Earn Out Revenue is less than US$4,200,000 but greater than US$2,100,000, such payment of the remaining US$1,000,000 or RMB equivalent shall be reduced proportionally for any shortfall of the Earn Out Revenue.3.2 Determination of Earn Out Revenue(a) For the purpose of the Recipient to calculate the Earn Out Revenue, the Recipient shall as promptly as practicable provide the Proprietor with a written statement of its calculation (the “Calculation Statement”) of the Earn Out Revenue for the relevant period(s).(b) Upon receiving a Calculation Statement, the Proprietor shall within ten (10) days either (i) notify the Recipient in writing that it agrees with the Calculation Statement or (ii) notify the Recipient in writing that it does not agree with the Calculation Statement and stating the grounds of their disagreement and their own calculation of the Earn Out Revenue for determination of the relevant part of the applicable assignment fee, together with a copy of any information used in making such calculation (the “Dispute Notice”). If the Recipient does not receive any Dispute Notice from the Proprietor within such ten (10) days period, the Proprietor shall be deemed to have agreed to the Calculation Statement and the Recipient’s calculation of the Earn Out Revenue for determination of the relevant part of the applicable assignment fee.(c) In the event a Dispute Notice is given by the Proprietor according to Section 3.2(b), the Proprietor and the Recipient shall meet and attempt in good faith to resolve the items or amounts in dispute (the “Disputed Portion”). If the Proprietor and the Recipient are unable to reach an agreement within twenty (20) days after receipt of the Dispute Notice by the Recipient, the Proprietor or the Recipient may request an Independent Advisor to review the Disputed Portion and compute the Earn Out Revenue for the relevant period(s) in question. In making its calculation, the Independent Advisor shall consider only the Disputed Portion (and to the extent required, any other items or amounts necessary to derive the Disputed Portion). Such determination shall be made within twenty (20) days after such request and shall be conclusive and binding on the Parties. The fees, costs and expenses of the Independent Advisor shall be borne by the Party whose calculation of the Earn Out Revenue for the relevant period(s) is furthest from the Independent Advisor’s calculation.(d) For the avoidance of doubt, before the Disputed Portion is finally determined pursuant to this Section 3, the Recipient shall have the right (but not the obligation) to pay to the Proprietor the undisputed portion of the Earn Out Revenue proportionally.Section 4. FURTHER ASSURANCE4.1 The Proprietor agrees to disclose all the Information known to the Proprietor to the Recipient, or any person nominated by the Recipient, and provide all other reasonable assistance and information, including but not limited to all the Technical Documentation, as may be reasonably necessary in order to assist Recipient, or its nominee, to develop, use and/or manufacture the Targeted Products.4.2 The Proprietor agrees that from the date of this Agreement, without the prior written consent of the Recipient, not:(a) to communicate or otherwise make available the Information to any third party; and/or(b) to use the Information for any purpose.4.3 The Proprietor undertakes that it shall not and shall procure the IGC Holders (as defined in the Lease Agreement) not to, participate, assist, be concerned with, engaged or interested in, any business or entity in any manner, directly or indirectly, which is in competition with any business activities (including but without limitation, research and development, manufacturing, the sale and distribution) in connection with the Target Products in the PRC or any other jurisdiction.4.4 If the Information disclosed by the Proprietor to the Recipient is not sufficient to enable the applications and/or manufacture of the Targeted Products properly, efficiently and in reasonable quantities, The Recipient may serve notice on the Proprietor to that effect, identifying the areas of deficiency in the Information disclosed. Should the Proprietor, in the reasonable opinion of the Recipient, fail in the four (4) week period following service of such notice to remedy such deficiencies, the Recipient may serve notice on the Proprietor requiring the payment of the sum identified in Section 3, and the Proprietor agrees to repay this sum within two weeks of receipt of such notice for payment.Section 5. REPRESENTATIONS AND WARRANTIES5.1 Each Party hereby represents and warrants to the other Party that: (a) it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder in accordance with such Party’s organizational documents and the laws of its jurisdiction; (b) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms; and (c) the execution, delivery and performance of this Agreement do not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it.5.2 The Proprietor hereby further warrants that:(a) it is the sole proprietor of the Information free and clear of any lien, claim, restriction, charge, security interest or other encumbrance;(b) it has taken all the necessary mechanisms to hold the Information in confidence;(c) it has not, either by act or omission, caused and permitted anything to be done which might endanger the title to and benefits of the Information;(d) it has not knowingly withheld from the Recipient knowledge of any circumstances that may endanger the title to and benefits of the Information;(e) it will not engage in any action that will be detrimental to the title to and benefits of the Information after the execution of this Agreement;(f) neither the practice of the Target Products nor the manufacture, use, sale or other exploitation of any Target Products infringes upon or may infringe upon any third-party intellectual property right(s);(g) it has as of the Effective Date disclosed to the Recipient all the Information known to it with respect to all Target Products, which information is accurate and complete; and(h) it is not aware that the Information, or any of it, is known, or as a result of any past action or default on its part, or that of anyone else, is likely to become known to any third parties.5.3 The Proprietor hereby agrees to indemnify, and to keep the Recipient and the Recipient’s respective Affiliates, members, stockholders, employees, agents and representatives indemnified, against all actions, claims, proceedings, costs and damages (including any damages or compensation) paid by the Recipient on the advice of its legal advisers to compromise or settle any claim and all legal costs and other expenses arising out of any breach of the representations, warranties and undertakings of the Proprietor under this Agreement or out of any claims by a third party based on any facts which if substantiated would constitute such a breach. The Proprietor further agrees that the Recipient’s indemnification under this Section would first come from the assignment fee (if any is available) to be paid under this Agreement before seeking remedy from the Proprietor or its shareholders and that the Proprietor’s shareholders’ obligations under this indemnification provision will be limited to their pro-rata share of the obligation based on their ownership position at the time of Closing.Section 6. EFFECTIVENESSThis Agreement shall become effective and binding on the Parties hereto as of the date of its execution by or on behalf of the Parties hereto.Section 7. SETTLEMENT OF DISPUTES7.1 Dispute. Any dispute, controversy or claim (each a “Dispute”) arising out of or relating to this Agreement or to any of the transactions contemplated hereby, whether such Dispute is premised on contract, tort, equity, or statute, shall be submitted to arbitration upon the request of any Party to the Dispute with notice to each other Party to the Dispute.7.2 Arbitration. The arbitration shall be conducted in Hong Kong under the auspices of the Hong Kong International Arbitration Centre (“HKIAC”) and under the UNCITRAL Arbitration Rules in accordance with the HKIAC Procedures for the Administration of International Arbitration (as amended from time to time and by the rest of this Agreement). There shall be a panel of three (3) arbitrators. The Proprietor and the Recipient shall each appoint one (1) arbitrator, and the third arbitrator shall be appointed by the HKIAC. The Parties hereby agree that the third arbitrator of the arbitration panel shall not be a national of the PRC or the United States of America. The language of the arbitration shall be English and Chinese. To the extent a translator is necessary during the arbitration, the Parties shall stipulate a neutral, official translator for the arbitration proceedings, acceptable to the HKIAC. If the Parties are unable to agree on an official translator, then HKIAC shall appoint one. The losing Party shall bear the costs of such translator.7.3 Cooperation of the Parties. Each Party to the arbitration shall cooperate with each other Party to the arbitration in producing information and documents requested by such other Party in connection with such Disputes, subject to privileges applicable to the Dispute or confidentiality obligations binding on such Party. The Parties shall prepare and execute a confidentiality agreement in connection with the production of any such information or documents.7.4 Costs of Arbitration. The costs of arbitration shall be borne by the losing Party, unless otherwise determined by the arbitration panel. The prevailing Party shall be entitled to recover its reasonable attorney’s fees and costs incurred in connection with the arbitration.7.5 Award. The award of the arbitration panel shall be a written and reasoned award. The award of the arbitration panel shall be final and binding upon the Parties, and the prevailing Party may apply to a court of competent jurisdiction for enforcement of such award.7.6 Performance of Obligations. The Parties shall continue to perform their respective obligations under this Agreement, except with respect to the part in dispute and under adjudication, and shall be permitted to exercise all rights under this Agreement notwithstanding the filing of an arbitration demand by one Party against another Party.Section 8. APPLICABLE LAWThis Agreement, the legal relations between the Parties and any Dispute, whether contractual or non-contractual, instituted by any Party with respect to matters arising under or in connection with or in respect of this Agreement shall be governed by, and construed in accordance with, the laws of the State of California without regard to conflicts of laws principles thereunder.Section 9. REGISTRATION OF AGREEMENTShould this Agreement be subject to any registration or approval requirement under the applicable laws and regulations of the People’s Republic of China, the Proprietor shall, at the Recipient’s expenses, submit relevant application documents as soon as commercially practicable following the Effective Date to the application registration authority for the purpose of registration or approval of this Agreement.Section 10. LANGUAGEThis Agreement is executed in English. A separate Chinese language version of this Agreement has prepared solely for the purpose of registration with the competent PRC authority. In the event there is any discrepancy between the two versions, the English execution version shall prevail.Section 11. AMENDMENTSExcept as otherwise permitted herein, this Agreement and its provisions may be amended, supplemented, changed, waived, discharged, modified or terminated only by a writing signed by each of the Parties.Section 12. NOTICESAll notices, claims, certificates, requests, demands and other communications under this Agreement shall be made in writing and shall be delivered to any Party hereto by hand or sent by facsimile, or sent, postage prepaid, by reputable overnight courier services at the following addresses (or at such other address for such Party as shall be specified by like notice), and shall be deemed given when so delivered by hand, or if sent by facsimile, upon receipt of a confirmed transmittal receipt, or if sent by overnight courier, five (5) days after delivery to or pickup by the overnight courier service:(a)If to the Proprietor:International Green Chip Co., Ltd. (英特格灵芯⽚（天津）有限公司)Address:Room 210, South Tower, Tianda Software Zone, 80 Fourth Avenue, Tianjin Development Area, Tianjin, PRCFax number:(86) 10 8280 0206Attention:Mr. ZHANG(b)If to the Recipient:iWatt Inc.Address:675 Campbell Technology Parkway, Suite 150 Campbell, CA 95008 USAFax number:(1) 408 341 0455Attention:Mr. James V McCanna (Chief Financial Officer)Section 13. SEVERABILITYIf any term or other provision of this Agreement is invalid, illegal, or incapable of being enforced by any applicable law or public policy, all other terms or provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereunder is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal, or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the transactions contemplated hereunder are consummated as originally contemplated to the greatest extent possible.Section 14. REMEDIES CUMULATIVE.The rights and remedies available under this Agreement or otherwise available shall be cumulative of all other rights and remedies and may be exercised successively.Section 15. COUNTERPART EXECUTIONThis Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement.[Remainder of the page intentionally left blank; signatures to follow]IN WITNESS WHEREOF, each of the Parties has caused its duly authorized representative to execute this Agreement as of the date first above written.BY:/s/ ZHANGName: ZHANGPosition: Legal Representativefor and on behalf of International Green Chip Co., Ltd.英特格灵芯⽚（天津）有限公司(with company’s chop)BY:/s/ James V McCannaName: James V McCannaPosition: CFO and Secretaryfor and on behalf of iWatt Inc.for and on behalf of iWatt Inc.SCHEDULE 1List of the Target Products1.LCDTV 8CH + Boost LED BLU Driver; and2.LCDTV TCON Bias PMIC products。
材料转移协议(“ MTA ”)
重要！请在提交订单前仔细阅读。
此为合同。
此材料转移协议（“MTA ”）由 （即一家 类型的组织机构，主要经营场所位于 ）（下文简称“买方”）与American Type Culture Collection （即一家非营利组织，主要经营场所位于10801 University Boulevard, Manassas, VA 20110-2209）（下文简称“ATCC ”）签订。
买方必须有一个获得批准的现用ATCC 帐户，方能下达订单。
此MTA 于各方最后签立之日起生效，并按以下所载条款与细则管辖所有ATCC 材料的购买和使用。
条款和细则定义“ATCC 材料”指购自ATCC 的材料，见ATCC 销售订单所载。
“ATCC 销售订单”指按照ATCC 不时确定的形式和格式就ATCC 材料提交的订单。
“生物材料”指单一或多种ATCC 材料、后代、未改性衍生物以及任何属于改性物质的未改性衍生物。
“商业用途”指向此MTA 签约方以外的人或实体销售、授权、出租、出口、转移或以其它形式分发生物材料，牟取经济利益或将生物材料用于其他商业目的和/或用途：(a) 向此MTA 签约方以外的人或实体提供服务，牟取经济利益；(b) 生产或制造供一般销售的产品，或在制造最终供一般销售的产品中使用的产品。
(c) 与ADME （ADME 的意思是吸收、分布、新陈代谢和排泄）检测相关；(d) 与药效或毒性检测相关，不包括筛检有可能纳入筛检分析系统的多细胞系，或在仅供内部研究用的系统中筛检多种化合物；(e) 与精通度检测服务相关，包括但不限于提供这样的服务：按照预定条件对比和评估同一或类似物品的校准或测试，来判定实验室的表现。
或 (f) 用于按照某项协议开展的研究，根据该协议，营利性实体对研究结果享有实际权利或或有权利。
具体而言，商业用途不包括业内赞助的学术研究。
“捐赠人”指将原始材料交给ATCC 寄存的组织机构和/或个人。
“业内赞助的学术研究”指由营利性机构赞助，在非营利组织进行，并由非营利性组织雇员开展的研究。
材料转移协议(“ MTA ”)
重要！请在提交订单前仔细阅读。
此为合同。
此材料转移协议（“MTA ”）由 （即一家 类型的组织机构，主要经营场所位于 ）（下文简称“买方”）与American Type Culture Collection （即一家非营利组织，主要经营场所位于10801 University Boulevard, Manassas, VA 20110-2209）（下文简称“ATCC ”）签订。
买方必须有一个获得批准的现用ATCC 帐户，方能下达订单。
此MTA 于各方最后签立之日起生效，并按以下所载条款与细则管辖所有ATCC 材料的购买和使用。
条款和细则定义“ATCC 材料”指购自ATCC 的材料，见ATCC 销售订单所载。
“ATCC 销售订单”指按照ATCC 不时确定的形式和格式就ATCC 材料提交的订单。
“生物材料”指单一或多种ATCC 材料、后代、未改性衍生物以及任何属于改性物质的未改性衍生物。
“商业用途”指向此MTA 签约方以外的人或实体销售、授权、出租、出口、转移或以其它形式分发生物材料，牟取经济利益或将生物材料用于其他商业目的和/或用途：(a) 向此MTA 签约方以外的人或实体提供服务，牟取经济利益；(b) 生产或制造供一般销售的产品，或在制造最终供一般销售的产品中使用的产品。
(c) 与ADME （ADME 的意思是吸收、分布、新陈代谢和排泄）检测相关；(d) 与药效或毒性检测相关，不包括筛检有可能纳入筛检分析系统的多细胞系，或在仅供内部研究用的系统中筛检多种化合物；(e) 与精通度检测服务相关，包括但不限于提供这样的服务：按照预定条件对比和评估同一或类似物品的校准或测试，来判定实验室的表现。
或 (f) 用于按照某项协议开展的研究，根据该协议，营利性实体对研究结果享有实际权利或或有权利。
具体而言，商业用途不包括业内赞助的学术研究。
“捐赠人”指将原始材料交给ATCC 寄存的组织机构和/或个人。
“业内赞助的学术研究”指由营利性机构赞助，在非营利组织进行，并由非营利性组织雇员开展的研究。
如何向《生物材料》杂志投稿
O D h t h a Im I O ． 1 9 7 8 ：9 6 ：7 5 — 8 1 ．
[1 1 】 挺艺 ， 夏 朝 霞 ， 祝 希 梅 ． 表 耐 麻 醉 卜老 年 性 … 内障 小 切 【】摘 除 及
‘
’
人 工 晶状 体 植 入 术临 床 观 察 [J 】． 1I__『圈 老 年 学 杂 忠 ， 2 0 0 3 ， 2 3 (1 0 )：
M e d ic i n e ． N 0 r t h C a r O Ii n a ， U S A V js _l jn a P r o f e s s o n C h —s t ja a n B a m a rd
D e p a rt m e n l O f C a rd io l h 0 阳 c ic S u rg e 吼 C a p e
E m a il：d M @ № a c u k
h t t p ：ⅣⅥ，w W ． e Is e V ie r ． c O m ，w p s ，仃n d ，e d it O r s h O m e e d it O r S ，w il l ia m s
美 国威 克森林 大 学 医 学院 再 生 医 学研 究 所 国际 事务部主 任 ，
Tb w n ． S O u t h A f ric a
V is it in q P r o f e s s O r ia I F e l lO w ， G r a d u a t e
S c h O O l O f B iO m e d ic a I E n g in e e rj n g ， U n iV e r s it y
何守志 ．
人
『l铀状 体 例
究 最 新 进 腱 [J 】． 继 续 医 学 教
英文论文转让合同范本
英文论文转让合同范本合同编号：___________甲方（转让方）：_____________________乙方（接受方）：_____________________鉴于甲方是以下论文的唯一作者及版权所有者：论文题目：_______________________________发表刊物：_______________________________发表日期：_______________________________甲乙双方本着平等自愿的原则，就上述论文的版权转让事宜达成如下协议：1. 转让内容甲方同意将其所持有的上述论文的全部或部分版权（具体转让范围详见附件），包括但不限于复制权、发行权、出租权、展览权、表演权、放映权、信息网络传播权、改编权、翻译权、汇编权等，转让给乙方。
2. 转让价格双方经协商一致，确定本次论文版权的转让价格为____________美元。
乙方应在本合同签订后____天内一次性支付至甲方指定账户。
3. 权利保证甲方保证其为上述论文的唯一作者及版权所有者，论文内容未侵犯任何第三方的知识产权或其他合法权益。
如因甲方原因导致论文涉及侵权纠纷，甲方应负责解决并承担相应责任。
4. 使用范围乙方有权在全球范围内使用上述论文版权，用于包括但不限于教学、研究、出版、传播等目的。
乙方在使用论文时，应注明原作者姓名并在合理范围内尊重作者的学术声誉。
5. 保密条款未经对方书面同意，任何一方不得向第三方泄露本合同以及与本合同相关的任何商业秘密和技术秘密。
6. 违约责任如一方违反本合同约定，需赔偿对方因此遭受的一切损失。
7. 法律适用与争议解决本合同的签订、解释、执行和争议解决均适用____国家/地区的法律。
如双方在合同履行过程中发生争议，应首先通过友好协商解决；协商不成时，任何一方均可向甲方所在地有管辖权的法院提起诉讼。
8. 其他事项本合同自双方签字盖章之日起生效。
本合同一式两份，甲乙双方各执一份，具有同等法律效力。
生物材料转移协议
生物材料转移协议根据（接受生物材料的单位，以下简称“乙方”）研究员（索取生物材料的研究者）的要求，（以下简称“甲方”）同意由甲方研究员提供××及与之相关的技术信息（以下简称“生物材料”，详见附件1）用于开展与该生物材料有关的合作研究工作。
根据《中华人民共和国合同法》和有关法律、法规，对上述生物材料转移事宜，甲、乙双方一致同意达成如下协议：，而且，该研究课题所发表的论文或其他形式的文献，研究员应为第一作者或通讯作者上述生物材料不能用于人体研究。
二、未经甲方书面许可，乙方不得将上述生物材料及其后代、其未经改变或修饰的衍生物（derivatives）、其变体（modifications）和由直接使用上述生物材料而产生的任何物质，用于任何目的和/或形式的商业用途，或为商业用途而进行的研究开发。
未经甲方书面许可，乙方及研究员领导的研究组的任何成员不得将上述生物材料、后代、衍生物、变体和物质用于第一条所列研究课题之外的任何用途。
三、未经甲方书面许可，乙方不得将上述生物材料及其后代、其未经改变或修饰的衍生物、其变体和由直接使用上述生物材料而产生的任何物质，提供给任何第三方和除乙方研究员及其领导的研究组的成员以外的任何人员。
四、甲方保留与上述生物材料及其后代、其未经改变或修饰的衍生物和由直接使用上述生物材料而产生的任何物质（以下简称“拥有所有权的生物材料”）相关的所有权利，包括任何包含、混合、或整合在变体中的拥有所有权的生物材料。
乙方同意在收到甲方通知后120天内或本协议第一条所述的研究课题结束后60天内停止使用上述拥有所有权的生物材料，并销毁。
五、乙方知道，甲方可能就上述生物材料申请专利。
除本协议约定之外，甲方没有以任何明示或暗示方式许可乙方使用其专利、专利申请、商业秘密或其他所有权等。
特别地，甲方未以任何明示或暗示方式许可乙方为商业目的使用上述生物材料或其相关专利。
六、上述生物材料仅可以在适当的安全条件下被使用。
生物材料转移协议书
生物材料转移协议书甲方（提供方）：_____________________________________地址：_____________________________________________联系电话：__________________________________________乙方（接收方）：_____________________________________地址：_____________________________________________联系电话：__________________________________________鉴于甲乙双方在平等、自愿的基础上，就甲方提供的生物材料的转移事宜达成如下协议：一、生物材料描述1.1 生物材料包括但不限于以下种类和数量：-材料名称：________________-数量：________________-特性描述：________________1.2 甲方保证所提供的生物材料是在合法和伦理范围内获得，且未侵犯第三方的任何权利。
二、使用目的2.1 乙方仅可将生物材料用于以下目的：_____________________________。
2.2 乙方不得将生物材料用于任何未经甲方书面同意的商业活动。
三、转移和接收3.1 甲方应在______________________之前将生物材料交付给乙方。
3.2 乙方在接收生物材料时应进行必要的检验，确认材料符合约定的标准和数量。
四、知识产权和保密4.1 甲方对生物材料拥有完整的知识产权，乙方接受此材料不影响甲方的权利。
4.2 双方须对交易过程中知悉的对方信息和数据进行保密，未经对方书面同意，不得泄露给第三方。
五、责任和义务5.1 甲方负责保证生物材料的质量和合法性，承担因材料问题引起的法律责任。
5.2 乙方应合理使用生物材料，确保其安全性，且遵守相关的法律法规。
六、违约责任6.1 如甲方提供的材料存在质量问题或不符合规定，应负责替换或修复。
2024版生物制药研发与转让合同
专业合同封面COUNTRACT COVER20XXP ERSONAL甲方：XXX乙方：XXX2024版生物制药研发与转让合同本合同目录一览1. 合同主体及定义1.1 甲方名称及定义1.2 乙方名称及定义1.3 丙方名称及定义1.4 相关术语定义2. 生物制药研发内容2.1 研发项目概述2.2 研发目标及里程碑2.3 研发团队及人员配置2.4 研发资金及使用计划3. 技术转让内容3.1 转让技术概述3.2 技术转让方式及范围3.3 技术转让费用及支付方式3.4 技术保密及知识产权保护4. 合作事项及分工4.1 甲方职责4.2 乙方职责4.3 丙方职责4.4 合作协调及决策机制5. 合同期限及终止条件5.1 合同期限5.2 合同终止条件5.3 合同终止后的处理事项6. 合同费用及支付方式6.1 研发费用6.2 技术转让费用6.3 其他费用6.4 支付方式及时间7. 风险评估及责任承担7.1 风险评估7.2 责任承担及赔偿方式8. 争议解决方式8.1 争议解决方式8.2 争议解决机构9. 合同的变更与解除9.1 合同变更条件9.2 合同解除条件10. 违约责任及赔偿10.1 违约情形10.2 赔偿方式及金额11. 合同的生效、修改及解除11.1 合同生效条件11.2 合同修改方式11.3 合同解除条件12. 保密条款12.1 保密内容12.2 保密期限12.3 保密泄露的赔偿方式13. 合同的继承与转让13.1 合同继承条件13.2 合同转让条件14. 法律适用及争议解决14.1 法律适用14.2 争议解决机构第一部分：合同如下：第一条合同主体及定义1.1 甲方名称及定义1.2 乙方名称及定义1.3 丙方名称及定义1.4 相关术语定义生物制药：指通过生物技术方法制成的药品，包括重组蛋白质药物、抗体药物、基因治疗药物等。
研发：指对生物制药进行科学研究、试验、生产和改进的过程。
技术转让：指乙方将拥有的生物制药技术转让给丙方的行为。
生物技术产品分析方法的转移
• 在制定具体方法转移方案之前，应该评估接收实验室的准备情况：
• 所需分析和支持设备、软件、关键试剂、标准品、对照品，以及分析人 员在相关分析技术方面的熟练程度，也要考虑所有材料、设备和分析人 员的资质确认状态。实验室的环境（某些方法）
●分析方法程序的详细描述 ● 分析方法验证报告 ● 之前的方法转移数据 ● 历史的方法性能信息 ● 用到的仪器的详细说明 ●历史数据（例如，谱图和色谱）
✓ 建立一个有效的沟通机制 ✓ 明确责任
二、分析方法转移先决条件
• Suggested AMT Responsibility Matrix
类型和数量取决于所转移的 分析方法以及接收实验室和 分析人员的现有经验。
按照质量体系要求 进行记录
评估执行该方法系统 适用性要求的能力
二、分析方法转移先决条件
一、分析方法转移简介
分析方法生命周期从选择到确认或验证的步骤
AMT可能发生在方法和产品生命 周期的任何阶段：
➢与产品研发期间或获批生产后整个 制造过程的转移有关， ➢更大技术转移过程的一部分。 ➢新实验室的质量控制放行和稳定性 实验，可能需要使用分析方法转移 来实现公司内部或外部（例如，合 同实验室）的方法转移。
符合系统适用性，确定定量限， TOST的偏差小于或等于10%，适当 的高浓度杂质置信区间为95%，或 者，对于低浓度杂质，实验室间均 值的绝对偏差在±25%之间。
杂质（定性，限度）
含量均匀性，纯度 和/或效力
“可变”执行 矩阵法
考虑了检验方法的结果变化，并且 针对高变量检验方法可能需要大量 的数据对比组。
三、策略及方案设计
高变量方法的具体分析方法转移研究设计 基于风险的方法来确定适当的样本量
《生物多样性公约》中文版
《生物多样性公约》的卡塔赫纳生物安全议定书本议定书缔约方，作为《生物多样性公约》(以下简称《公约》)的缔约方，忆及《公约》第19条第3和第4款、第8(g)条和第17条，又忆及《公约》缔约方大会1995年11月17日第II/5号决定要求订立一项生物安全议定书，其具体侧重点应为凭借现代生物技术获得的、可能对生物多样性的保护和可持续使用产生不利影响的任何改性活生物体的越境转移问题，特别是着手拟定适宜的提前知情同意程序，以供审议，重申《关于环境与发展的里约宣言》原则15中所规定的预先防范办法,意识到现代生物技术扩展迅速,公众亦日益关切此种技术可能会对生物多样性产生不利影响,同时还需顾及对人类健康构成的风险,认识到如能在开发和利用现代生物技术的同时亦采取旨在确保环境和人类健康的妥善安全措施，则此种技术可使人类受益无穷，亦认识到起源中心和遗传多样性中心对于人类极为重要,考虑到许多国家、特别是发展中国家此方面能力有限，难以应付改性活生物体所涉及的已知和潜在风险的性质和规模，认识到贸易协定与环境协定应相辅相成,以期实现可持续发展,强调不得将本议定书解释为缔约方根据任何现行国际协定所享有的权利和所承担的义务有任何改变,认为上述陈述无意使本议定书附属于其他国际协定，兹协议如下：第 1 条目标本议定书的目标是依循《关于环境与发展的里约宣言》原则15所订立的预先防范办法,协助确保在安全转移、处理和使用凭借现代生物技术获得的、可能对生物多样性的保护和可持续使用产生不利影响的改性活生物体领域内采取充分的保护措施，同时顾及对人类健康所构成的风险并特别侧重越境转移问题。
第 2 条一般规定1. 每一缔约方应为履行本议定书为之规定的各项义务采取必要和适当的法律、行政和其他措施。
2. 各缔约方应确保在从事任何改性活生物体的研制、处理、运输、使用、转移和释放时，防止或减少其对生物多样性构成的风险，同时亦应顾及对人类健康所构成的风险。
3. 本议定书的任何规定不得以任何方式妨碍依照国际法所确立的各国对其领海所拥有的主权以及国际法所规定的各国对其专属经济区及其大陆架所拥有的主权和管辖权，亦不得妨碍所有国家的船只和航空器依照国际法和有关国际文书所享有的航行权和航行自由。
材料议MTA料转移协议A
改性物质和未改性衍生物：买方的研究员只能在如下情况下制造、使用和转移改性物质和未改性衍生物：
买方研究员的非商业用途研究项目。改性物质和未改性衍生物只能在买方的研究员实验室中，由买方的研究员针对他/
她的研究项目来制造和使用。除下文规定之外，买方只能依据任何捐赠者权利和 CAR 限制规定，将此类改性物质和未 改性衍生物转移给 CRO，并只能用于与买方研究员的研究项目相关的用途，任何此类 CRO 必须同意正如本协议的买方 那样，受本 MTA 的条款和条件约束，且不得进一步转移此类材料。未经 ATCC 事先书面同意，不得将此材料进行后续 转移或用于商业用途。在完成合同规定的任何研究之后，买方应要求 CRO 销毁材料，或将材料归还给买方的研究员。
补偿
如果买方是联邦或州级非营利组织，或依法被禁止承担上述段落所规定补偿义务的外国机构： 由买方及其接收方使用、接收、操作、贮存、转移、弃置生物材料以及其它相关活动而造成的或与之有关的所有第三方索赔、损 失、费用和损害赔偿，包括合理的律师费（统称“索赔”），均由买方承担全部责任，但买方的责任不包括因 ATCC 的重大过失 或故意失当造成的索赔；如果买方是美国联邦政府或州级机构，或外国同等组织机构，那么该买方所承担的责任仅限于联邦侵权 索赔法案 (Federal Tort Claims Act)，28 U.S.C.（《美国法典》）§§ 2671 等或等同的适用州或外国法律所规定的范围。
利益或将生物材料用于其他商业目的和/或用途：(a) 向本 MTA 签约方以外的人士或实体提供服务，以牟取经济利益；(b) 生 产或制造供一般销售的产品，或在制造最终供一般销售的产品中使用的产品；或 (c) 与精通度检测服务相关，包括但不限
于提供以下服务：按照预定条件对比和评估相同或类似物品的校准或测试，来判定实验室的表现。 “捐赠者”是指提供与 ATCC 材料相关的技术和/或专利权，或向 ATCC 提供原始材料以用于寄存的任何组织机构、实体和/或人
2024年生物制药研发与生产协议
20XX 专业合同封面COUNTRACT COVER甲方：XXX乙方：XXX2024年生物制药研发与生产协议本合同目录一览第一条定义与解释1.1 合同双方1.2 合同标的1.3 合同期限第二条研究内容2.1 研究项目2.2 研究目标2.3 研究方法第三条生产内容3.1 生产规模3.2 生产工艺3.3 质量控制第四条技术转移与知识产权4.1 技术转移4.2 知识产权归属4.3 知识产权保护第五条合作机制与沟通渠道5.1 合作机制5.2 沟通渠道5.3 决策程序第六条费用与支付6.1 研究经费6.2 生产成本6.3 支付方式第七条成果分享与分配7.1 成果分享7.2 成果分配7.3 分配比例第八条保密义务8.1 保密内容8.2 保密期限8.3 保密泄露责任第九条违约责任9.1 违约情形9.2 违约责任9.3 违约赔偿第十条争议解决10.1 争议类型10.2 解决方式10.3 争议解决机构第十一条强制性条款11.1 法律法规11.2 强制性规定11.3 合规要求第十二条合同的变更与终止12.1 合同变更12.2 合同终止12.3 终止后的事宜第十三条附则13.1 合同的生效13.2 合同的份数13.3 合同的修改第十四条完整性与独立性14.1 合同的完整性14.2 合同的独立性14.3 合同的互不依赖性第一部分：合同如下：第一条定义与解释1.1 合同双方本合同双方甲方为（甲方名称），乙方为（乙方名称）。
1.2 合同标的本合同的标的为甲方委托乙方进行的（具体研究项目名称）的研究与生产。
1.3 合同期限本合同自双方签字之日起生效，有效期为（具体期限年数）年，自合同生效之日起计算。
第二条研究内容2.1 研究项目甲方向乙方委托的研究项目为（详细研究内容和目标）。
2.2 研究目标乙方需按照甲方的要求，完成研究项目的研发，实现（详细研究目标和成果）。
2.3 研究方法乙方将采用（详细研究方法和工艺）进行研究，并提交研究报告和成果。
转让英文合同范本
转让英文合同范本Transfer ContractThis Transfer Contract (the "Contract") is made and entered into as of [date] and between:Party A (the "Transferor"):Name: [Transferor's Name]Address: [Transferor's Address]Contact Information: [Telephone Number and E Address]Party B (the "Transferee"):Name: [Transferee's Name]Address: [Transferee's Address]Contact Information: [Telephone Number and E Address]1. Subject Matter of TransferParty A agrees to transfer to Party B, and Party B agrees to acquire from Party A, the following assets/rights/obligations (the "Subject Matter"): [Describe the specific assets, rights, or obligations being transferred in detl]2. ConsiderationIn consideration for the transfer of the Subject Matter, Party B shall pay to Party A the sum of [amount] (the "Consideration"). The Consideration shall be pd in the following manner:[Specify the payment terms, such as the schedule and method of payment]3. Representations and WarrantiesBoth Party A and Party B represent and warrant as follows:3.1 They have the full legal capacity and authority to enter into and perform this Contract.3.2 The transfer of the Subject Matter is not in violation of any law, regulation, contract, or other obligation.3.3 All information provided them in connection with this Contract is true, accurate, and plete.4. Delivery and AcceptanceParty A shall deliver the Subject Matter to Party B within [specified time period]. Party B shall inspect and accept the Subject Matter within [specified time period] after delivery. If Party B has any objections, it shall notify Party A in writing within the acceptance period.5. IndemnificationParty A shall indemnify and hold Party B harmless from and agnst any losses, damages, liabilities, costs, and expenses arising from or related to any breach of the representations and warranties made Party A in this Contract.6. ConfidentialityBoth parties agree to keep the terms and conditions of this Contract confidential and not to disclose them to any third party without the prior written consent of the other party, except as required law.7. Governing Law and Dispute ResolutionThis Contract shall be governed and construed in accordance with the laws of [jurisdiction]. Any dispute arising out of or in connection with this Contract shall be resolved through friendly negotiation. If negotiation fls, the dispute shall be submitted to arbitration/ litigation in accordance with the applicablerules/laws.8. Entire AgreementThis Contract constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations, representations, and agreements.9. Amendments and WversAny amendment or wver of this Contract shall be in writing and signed both parties.IN WITNESS WHEREOF, the parties have executed this Contract as of the date first above written.Party A (Signature): ____________________Party B (Signature): ____________________Date: ____________________Please note that the above is a basic template and should be tlored to the specific circumstances and requirements of the transfer. It is remended to seek legal advice before entering into any legally binding contract.。
(全篇)知识产权转移协议英文版
(全篇)知识产权转移协议英文版Assignment of Intellectual Property AgreementThis document serves as a formal agreement between the parties involved for the transfer of intellectual property rights. The purpose of this agreement is to outline the terms and conditions under which the transfer of intellectual property rights will take place.1. Parties Involved:- The "Assignor" refers to the party transferring the intellectual property rights.- The "Assignee" refers to the party receiving the intellectual property rights.2. Description of Intellectual Property:- The intellectual property being transferred includes, but is not limited to, patents, trademarks, copyrights, and trade secrets.3. Transfer of Rights:- The Assignor agrees to transfer all rights, title, and interest in the intellectual property to the Assignee.- The Assignee agrees to accept the transfer of rights and to abide by any conditions set forth in this agreement.4. Consideration:- In consideration of the transfer of rights, the Assignee agrees to pay the Assignor a specified amount as agreed upon by both parties.5. Representations and Warranties:- The Assignor represents and warrants that they are the sole owner of the intellectual property and have the right to transfer the rights.- The Assignor further represents and warrants that there are no existing claims or encumbrances on the intellectual property.6. Governing Law:- This agreement shall be governed by the laws of [Jurisdiction] and any disputes arising out of this agreement shall be resolved through arbitration.7. Confidentiality:- Both parties agree to keep the terms of this agreement confidential and not disclose any information to third parties without prior written consent.8. Term and Termination:- This agreement shall be effective as of the date of signing and shall remain in effect until the transfer of rights is completed.- Either party may terminate this agreement in writing if the other party breaches any of the terms outlined herein.9. Entire Agreement:- This agreement constitutes the entire understanding between the parties with respect to the transfer of intellectual property rights and supersedes any prior agreements or understandings.In witness whereof, the parties hereto have executed this agreement as of the date first above written.[Signature of Assignor] [Signature of Assignee]_________________________ _________________________ Assignor Assignee。
吉满生物 H_ROR2 CHO-K1 Cell Line说明书
产品手册H_ROR2 CHO-K1 Cell LineH_ROR2 CHO-K1细胞系For research use only！本品仅供科研使用，严禁用于治疗！版本号：V2.8目录一、产品基本信息及组分 (3)二、包装、运输及储存 (3)三、材料准备 (3)1.细胞培养、冻存、复苏试剂准备 (3)2.试剂耗材准备 (3)四、细胞培养、复苏、冻存 (4)1.H_ROR2 CHO-K1 Cell Line细胞复苏 (4)2.H_ROR2 CHO-K1 Cell Line细胞传代 (4)3.H_ROR2 CHO-K1 Cell Line细胞冻存 (5)五、验证结果 (6)1.流式检测蛋白表达 (6)使用许可协议： (7)附录1 H_ROR2氨基酸序列 (8)一、产品基本信息及组分基本信息产品编号产品名称规格GM-C19164H_ROR2 CHO-K1 Cell Line5E6 Cells/mL 组成成分产品编号产品名称规格数量储存Fetal Bovine Serum500 mL Thermo/10099141F12K 500 mL BOSTER/PYG0036Human ROR2 Antibody / R&D SYSTEMS/MAB20641重要仪器细胞计数仪ThermoFisher Scientific/Countess 3流式细胞仪常州必达科生物科技有限公司/BeamCyte-1026四、细胞培养、复苏、冻存1.H_ROR2 CHO-K1 Cell Line细胞复苏a)细胞冻存密度为5 × 106 cells/mL，冻存管分装1 mL。
b)在37℃水浴锅预热培养基，加入预热完全培养基5 mL到15 mL离心管。
c)从液氮中取出冻存的细胞并迅速放入37℃恒温水浴锅，将细胞液面浸至水面以下不断摇动至融化。
d)用70%乙醇擦拭冻存管外部以降低污染的几率。
e)在生物安全柜或超净台中将冻存管中的细胞悬液转移到预先加有预热好的15 mL离心管中，轻轻混匀，1000 rpm，离心5 min使细胞沉淀，弃上清。
菌株材料运输转移协议
单位菌株材料运输转移协议
甲方：
乙方：
为满足临床诊断、GCP（临床实验项目）、科研等需求，甲方允许乙方科室提出申请向院外检测机构运输转移菌株。
包括：人和动物病原微生物分类与风险等级中除一、二类病原微生物以外的细菌、酵母菌、以及丝状真菌。
经甲方与乙方平等协商，就菌株外送事宜达成以下协议：
1.需送院外检测机构进行病原体检测或鉴定的生物类标本应由乙方向医院总务部门提出申请或乙方科室派专人专车送检，不得使用公共交通工具，病人或家属不可送检；送检人员应接受生物安全培训，并按要求做好个人防护，送检标本必须使用专用容器存放，并注意防止标本震荡或外泄，标本不得裸露在外送检。
2.该批微生物或菌株及其复制品不得用于商业用途。
乙方不得向指定检测机构外的第三方散布、转让该批菌株及其复制品。
3.本协议遵守国家对于微生物菌株资源管理方面的相关法律法规，如有冲突以国家法律法规为准。
甲方(盖章)：乙方(盖章)：
代表人（签字）：代表人（签字）：。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
XXXXX生物材料转移协议本协议确定了关于提供方向接收方所供应的由研究人员研制的特定生物材料的规定，希望在本协议的条款和细则的约束下该材料使用于非商业性研究目的。
此材料转移协议（MTA）由__________________，即一家__________________类型的组织机构(接收方)，与XXXXX（提供方）签订。
此协议于各方最后签立之日起生效，并按以下条款与细则管辖生物材料的转移和使用。
一、定义1.提供方： XXXXX2.提供方科学家：______________3.接收方：______________4.接收方科学家：______________5.原始材料：______________6.材料：原始材料、后代和未改性衍生物，其中不包括（1）改性物质（2）由接收方使用材料创制的除了改性物质、后代和未改性衍生物之外的物质。
7.后代：指源自材料的未改性后代，如源自病毒的病毒、源自细胞的细胞、源自微生物的微生物。
8.未改性衍生物：指由接收方创造的各种物质，构成一种未改性的功能亚基或原始材料的表达产物，例如未改性细胞系的亚克隆、原始材料的纯化或分馏子集，由提供方所供DNA/RNA 表达的蛋白质，或由杂交瘤细胞系分泌的单克隆抗体。
9.改性物质：指接收方创制的、包含和（或）容纳材料的物质。
10.商业用途：指向营利性机构销售、出租、授权、转移材料或其改性物质，也包括接收方在内的任何机构使用材料进行合同研究、筛选化合物库、或制造供一般销售的产品，或进行研究行为，目的是向营利性机构销售、出租、授权、转移材料或改性物质。
但是，由企业赞助的学术性研究不应被认为是材料或改性物质的商业性用途，除非满足上述对商业用途所定义的情况。
二、协议条款1.提供方保留对材料的所有权，包括任何包含或混有改性物质的材料。
2.接收方对以下材料拥有所有权：（1）改性物质（提供方对其中所含生物材料的权利保留拥有全的情况除外）；（2）使用材料或改性物质创造的非后代、未改性衍生物及改性物质（即不包含原始材料、后代或未改性衍生物）。
如上述两种情况为提供方与接收方的合作成果，则可对共同所有权进行商议。
3.接收方及接收方科学家同意如下细则，本材料：（1）仅用于教学或学术性研究；（2）不得使用于人体、临床试验或者未经提供方书面同意而用于人体的诊断；（3）仅可在接收方研究人员的实验室中使用，并且在接收方科学家或其直接监管人员的指导下使用；（4）未经提供方事先书面同意不得将材料转移给接收方机构内的任何人。
4.接收方及接收方科学家同意向提供方提交在接收方科学家监管下工作人员的任何关于材料的请求。
在某种程度上该材料可供其他科学家使用，提供方或提供方科学家同意制备该材料给其他科学家用于重复接收方的研究实验，但须与提供方签订该协议的独立实施函件或者与此协议条款相一致的其他协议，并且这些科学家需向提供方补偿制备和配送材料的相关成本。
5.（1）除原始材料的后代、未改性衍生物和改性物质外，接收方和（或）接收科学家有权不受限制地分配由接收方通过使用原始材料研制的产物。
（2）在本协议的独立实施函件（或一份至少可作为保护提供方权利的协议）指导下，接收方可将改性物质分配给非营利组织机构用于单纯性的科研与教学。
（3）未经提供方的书面同意，接收方和（或）接收方科学家不得将改性物质投入商业用途。
接收方应认识到，此类商业用途需获得提供方的商业许可，提供方拥有对包含在改性物质中的材料的所有权，但没有义务对其授予商业许可。
该项条款将防止接收方在其知识产权声明中对改性物质、或其制造方法及使用方法授予商业许可。
6. 接收方需知晓该材料有可能用于专利申请。
除非在本协议中明确规定，否则接收方不拥有提供方对专利、专利申请书、商业秘密或其他所有权的任何明示或默示的许可及其他权利，包括提供方对该材料所做的任何改变形式。
特别是，接收方并未获得任何明示或默示的许可表明其可将提供方的材料、改性物质或任何相关的专利投入商业用途。
7.如果接收方拟将该材料或改性物质投入商业用途，须同意，在此之前与提供方商议并确立一份商业许可的条款。
接收方应了解，提供方没有义务授予接收方此类许可，而且可能会授予他人一些专用性或非专用性的商业许可，或出售、转让材料的全部/部分权利给任何第三方，并受到已有的所有权和对政府应尽的义务条款的约束。
8. 接收方通过使用该材料而获得的发明可自由提出专利申请，但需告知提供方在专利申请中已声明的该材料的改性物质、制备方法或用途等。
9. 根据本协议提供的任何材料都被理解为实验性质，并可能具有危险性。
提供方对此不作任何陈述和任何明示或默示的保证。
对于任何适销性、特定目的适用性以及不侵犯任何专利权、版权、商标或其他所有权的用途，提供方不做任何明示或默示的保证。
10. 接收方应对可能发生在该材料使用、储存或弃置过程中造成的损害承担赔偿责任，法律禁止范围的除外。
接收方在使用该材料时发生重大过失、故意的不当行为所造成的任何损失、索赔、需求，或有关的所有第三方索赔、损失和损害，提供方将不承担任何责任，法律另有规定的除外。
11. 此协议不得被解释为因使用该材料或改性物质而阻止或延误了研究结果的发表。
接收方科学家同意在所有的出版物中对材料来源予以适当的致谢。
12. 接收方同意遵照法律法规使用该材料。
13. 本协议在以下日期到来之初即可终止：（1）当本材料可轻易从第三方如试剂公司或公共仓库获得时；（2）当接收方已完成利用本材料进行的最新研究时；（3）任何一方书面通知中提出的三十日期限或失效日前的期限，或（4）在实施函件中指定的日期。
如果：1）协议是因条款13（1）而终止，则接收方从后续可用的来源中获得该材料时受到的限制性条款最少；2）协议是因13（2）或（4）终止，则接收方停止使用该材料并在提供方的指导下，返还或销毁所有剩余材料。
接收方可自行决定，销毁或保留改性物质，但要受到其相应的条款约束；3）提供方在13（3）的情况下终止协议，且不是因为违反协议或类似于健康风险、专利侵权等原因，则提供方将根据接收方要求将合同有效终止日期延长一年，以使接收方完成相应研究。
截止到合同有效终止日期，或延期后的有效终止日期，接收方应停止使用材料，并在提供方的要求和指引下返还或销毁剩余材料。
接收方可自行决定，销毁或保留改性物质，但要受到其相应的条款约束。
14. 提供该材料原则上是不收取费用的，但是，为补偿提供方制备及配送该材料的成本，接收方可适当支付部分运输费用。
如提供方要求收取费用，则需在单独的实施函件中注明数额。
15.本协议中英文版本各2份，提供方和接收方各执1份，均具有同等法律效力。
各方的授权代表在下面签字，即表示他们已经阅读、理解并同意此材料转移协议中所载的条款和细则，特此签字为证。
提供方: XXXXX地址: XXXXXX，510275提供方授权人:职务:签字: 日期:提供方科研人员：签字: 日期:接收方:地址:接收方授权人:职务:签字: 日期:接收方科研人员：签字: 日期:******* UNIVERSITYUNIFORM BIOLOGICAL MATERIAL TRANSFER AGREEMENTThis Agreement sets out the understanding of the parties with respect to the provision of certain biological material created by researchers at the Provider to the Recipient, which wishes to use the material for non-commercial research purposes subject to the terms and conditions of this Agreement. This Material Tran sfer Agreement (“MTA”) is between the___________, a __________ type organization (“Recipient”) and the ******* University (“Provider”).This MTA is effective as of the last date of execution by the parties and governs the transfer and use of all Biological Materials under the terms and conditions set forth below.Definitions1. PROVIDER: ******* University2. PROVIDER SCIENTIST:3. RECIPIENT:4. RECIPIENT SCIENTIST:5. ORIGINAL MATERIAL:6. MATERIAL:ORIGINAL MATERIAL, PROGENY，and UNMODIFIED DERIV A TIVES. The MATERIAL shall not include: (a) MODIFICA TIONS, or (b) Other substances created by the RECIPIENT through the use of the MATERIAL which are not MODIFICA TIONS, PROGENY, or UNMODIFIED DERIV ATIVES.7. PROGENY: Unmodified descendant from the MATERIAL, such as virus from virus, cell from cell, or organism from organism.8. UNMODIFIED DERIVATIVES: Substances created by the RECIPIENT which constitute an unmodified functional subunit or product expressed by the ORIGINAL MA TERIAL. Some examples include: subclones of unmodified cell lines, purified or fractionated subsets of the ORIGINAL MATERIAL, proteins expressed by DNA/RNA supplied by the PROVIDER, or monoclonal antibodies secreted by a hybridoma cell line.9. MODIFICA TIONS: Substances created by the RECIPIENT which contain/incorporate the MATERIAL.10. COMMERCIAL PURPOSES: The sale, lease, license, or other transfer of the MA TERIAL or MODIFICATIONS to a for-profit organization. COMMERCIAL PURPOSES shall also include uses of the MATERIAL or MODIFICATIONS by any organization, including RECIPIENT, to perform contract research, to screen compound libraries, to produce or manufacture products for general sale, or to conduct research activities that result in any sale, lease, license, or transfer of the MA TERIAL or MODIFICATIONS to a for-profit organization. However, industrially sponsored academic research shall not be considereda use of the MATERIAL or MODIFICATIONSforCOMMERCIAL PURPOSES per se unless any of the above conditions of this definition are met.Material Transfer1. The PROVIDER retains ownership of the MATERIAL, including any MATERIAL contained or incorporated in MODIFICA TIONS.2. The RECIPIENT retains ownership of: (a) MODIFICA TIONS (except that, the PROVIDER retains ownership rights to the MATERIAL included therein), and (b) those substances created through the use of the MATERIAL or MODIFICA TIONS, but which are not PROGENY, UNMODIFIED DERIVATIVES or MODIFICA TIONS (i.e., do not contain the ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIV A TIVES). If either 2 (a) or 2 (b) results from the collaborative efforts of the PROVIDER and the RECIPIENT, joint ownership may be negotiated.3. The RECIPIENT and the RECIPIENT SCIENTIST agree that the MATERIAL: (a) is to be used solely for teaching and academic research purposes; (b) will not be used in human subjects, in clinical trials, or for diagnostic purposes involving human subjects without the written consent of the PROVIDER; (c) is to be used only at the RECIPIENT organization and only in the RECIPIENT SCIENTIST's laboratory under the direction of the RECIPIENT SCIENTIST or others working under his/her direct supervision; and (d) will not be transferred to anyone else within the RECIPIENT organization without the prior written consent of the PROVIDER.4. The RECIPIENT and the RECIPIENT SCIENTIST agree to refer to the PROVIDER any request for the MATERIAL from anyone other than those persons working under the RECIPIENT SCIENTIST's direct supervision. To the extent supplies are available, the PROVIDER or the PROVIDER SCIENTIST agrees to make the MATERIAL available, under a separate implementing letter to this Agreement or other agreement having terms consistent with the terms of this Agreement, to other scientists who wish to replicate the RECIPIENT SCIENTIST’s research; provided that such other scientists reimburse the PROVIDER for any costs relating to the preparation and distributionof the MATERIAL.5.(a) The RECIPIENT and/or the RECIPIENT SCIENTIST shall have the right, without restriction, to distribute substances created by the RECIPIENT through the use of the ORIGINAL MATERIAL only if those substances are not PROGENY, UNMODIFIED DERIV A TIVES, or MODIFICA TIONS.(b) Under a separate implementing letter to this Agreement (or an agreement at least as protective of the PROVIDER's rights), the RECIPIENT may distribute MODIFICATIONS to NON-PROFIT ORGANIZATION(S) for research and teaching purposes only.(c) Without written consent from the PROVIDER, the RECIPIENT and/or the RECIPIENT SCIENTIST may NOT provide MODIFICATIONS for COMMERCIAL PURPOSES. It is recognized by the RECIPIENT that such COMMERCIAL PURPOSES may require a commercial license from the PROVIDER and the PROVIDER has no obligation to grant a commercial license to its ownership interest in the MATERIAL incorporated in the MODIFICATIONS. Nothing in this paragraph, however, shall prevent the RECIPIENT from granting commercial licenses under the RECIPIENT's intellectual property rights claiming such MODIFICATIONS, or methods of their manufacture or their use.6. The RECIPIENT acknowledges that the MATERIAL is or may be the subject of a patent application. Except as provided in this Agreement, no express or implied licenses or other rights are provided to the RECIPIENT under any patents, patent applications, trade secrets or other proprietary rights of the PROVIDER, including any altered forms of the MATERIAL made by the PROVIDER. In particular, no express or implied licenses or other rights are provided to use the MATERIAL, MODIFICATIONS, or any related patents of the PROVIDER for COMMERCIAL PURPOSES.7. If the RECIPIENT desires to use or license the MATERIAL or MODIFICA TIONS forCOMMERCIAL PURPOSES, the RECIPIENT agrees, in advance of such use, to negotiate in good faith with the PROVIDER to establish the terms of a commercial license. It is understood by the RECIPIENT that the PROVIDER shall have no obligation to grant such a license to the RECIPIENT, and may grant exclusive or non-exclusive commercial licenses to others, or sell or assign all or part of the rights in the MATERIAL to any third party(ies), subject to any pre-existing rights held by others and obligations to the government.8. The RECIPIENT is free to file patent application(s) claiming inventions made by the RECIPIENT through the use of the MATERIAL but agrees to notify the PROVIDER upon filing a patent application claiming MODIFICATIONS or method(s) of manufacture or use(s) of the MATERIAL.9. Any MATERIAL delivered pursuant to this Agreement is understood to be experimental in nature and may have hazardous properties. The PROVIDER MAKES NO REPRESENTA TIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, 'TRADEMARK, OR OTHER PROPRIETARY RIGHTS.10. Except to the extent prohibited by law, the RECIPIENT assumes all liability for damages which may arise from its use, storage or disposal of the MATERIAL. The PROVIDER will not be liable to the RECIPIENT for any loss, claim or demand made by the RECIPIENT, or made against the RECIPIENT by any other party, due to or arising from the use of the MATERIAL by the RECIPIENT, except to the extent permitted by law when caused by the gross negligence or willful misconduct of the PROVIDER.11.This agreement shall not be interpreted to prevent or delay publication of research findings resulting from the use of the MATERIAL or the MODIFICATIONS. The RECIPIENT SCIENTIST agrees to provide appropriate acknowledgment of the source of the MA TERIAL in all publications.12.The RECIPIENT agrees to use the MATERIAL in compliance with all applicable statutes and regulations.13. This Agreement will terminate on the earliest of the following dates: (a) when the MA TERIAL becomes generally available from third parties, for example, through reagent catalogs or public depositories, or (b) on completion of the RECIPIENT's current research with the MATERIAL, or (c) on thirty (30) days written notice by either party to the other, or (d) on the date specified in an implementing letter, provided that:（1）if termination should occur under Section 13(a), the RECIPIENT shall be bound to the PROVIDER by the least restrictive terms applicable to the MATERIAL obtained from thethen-available sources; and（2）if termination should occur under 13(b) or (d) above, the RECIPIENT will discontinue its use of the MATERIAL and will, upon direction of the PROVIDER, return or destroy any remaining MATERIAL. The RECIPIENT, at its discretion, will also either destroy the MODIFICA TIONS or remain bound by the terms of this agreement as they apply to MODIFICA TIONS;（3）in the event the PROVIDER terminates this Agreement under 13(c) other than for breach of this Agreement or for cause such as an imminent health risk or patent infringement, the PROVIDER will defer the effective date of termination for a period of up to one year, upon request from the RECIPIENT, to permit completion of research in progress. Upon the effective date of termination, or if requested, the deferred effective date of termination, RECIPIENT will discontinue its use of theMATERIAL and will, upon direction of the PROVIDER, return or destroy any remaining MATERIAL. The RECIPIENT, at its discretion, will also either destroy the MODIFICA TIONS or remain bound by the terms of this agreement as they apply to MODIFICATIONS.14. The MATERIAL is provided at no cost, or with an optional transmittal fee solely to reimburse the PROVIDER for its preparation and distribution costs. If a fee is requested by the PROVIDER, the amount will be indicated in an implementing letter.This is agreed to by the Following Parties:PROVIDER INSTITUTION:******* UniversityADDRESS: NO.74,zhongshan 2nd road, Guangzhou, China, 510080Name of Authorized Official: Dan LiangTitle of Authorized Official: Director, SYSU Medical Science OfficeSignature: ___________________________ Date: _________ READ and UNDERSTOODby PROVIDER’s SCIENTIST:Signature: ___________________________ Date: _________RECIPIENT INSTITUTION:ADDRESS:Name of Authorized Official:Title of Authorized Official:Signature: ___________________________ Date: _________READ and UNDERSTOODby RECIPIENT’s SCIENTIST:Signature: ___________________________ Date: _________。